RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GRIMALDI L
Collezione AOU San Luigi di Orbassano

Items : 6

Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study. in Journal of neurology / J Neurol. 2024 Jan;271(1):340-354. doi: 10.1007/s00415-023-11955-0. Epub 2023 Sep 16.

2024
AOU San Luigi di Orbassano

Zanetta C; Perini D; Brescia Morra V; Cordioli C; Granella F; Malucchi S; Totaro R; Valente MR; Conte A; Grimaldi L; Filippi M; Santoni L;

Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study. in Journal of neurology / J Neurol. 2023 Oct;270(10):4687-4696. doi: 10.1007/s00415-023-11820-0. Epub 2023 Jul 5.

2023
AOU San Luigi di Orbassano

Amato MP; Bergamaschi R; Centonze D; Mirabella M; Marfia GA; Totaro R; Lus G; Brescia Morra V; Aguglia U; Comi C; Cavalla P; Zaffaroni M; Rovaris M; Grimaldi LM; Leoni S; Malucchi S; Baldi E; Romano M; Falcini M; Perini P; Assetta M; Portaccio E; Sommacal S; Olivieri N; Parodi F; Todaro DS; Grassivaro N; Farina A; Mondino MM; et alii...

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study. in Journal of neurology / J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28.

2022
ASL Cuneo 1
AOU San Luigi di Orbassano

Bellantonio P; Totaro R; Vianello M; Cavalla P; Granella F; Di Sapio A; Bertolotto A; Maimone D; Bergamaschi R; Lus G; Solaro C; Amato MP; Rovaris M; Gasperini C; Ferrò MT; Pesci I; Aguglia U; Maniscalco GT; Sola P; Conte A; De Luca G; Cottone S; Salemi G; Lugaresi A; Inglese M; Bonavita S; Grimaldi LM; Marfia GA; Brescia Morra V; et alii...

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study. in Journal of neurology / J Neurol. 2021 Aug;268(8):2922-2932. doi: 10.1007/s00415-021-10455-3. Epub 2021 Feb 22.

2021
AOU San Luigi di Orbassano

Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; et alii...

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. in Journal of neurology / J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

2018
AOU San Luigi di Orbassano

Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;

Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology / Neurol Sci. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29.

2014
AOU San Luigi di Orbassano

Bertolotto A; Capobianco M; Amato MP; Capello E; Capra R; Centonze D; Di Ioia M; Gallo A; Grimaldi L; Imberti L; Lugaresi A; Mancinelli C; Marrosu MG; Moiola L; Montanari E; Romano S; Musu L; Paolicelli D; Patti F; Pozzilli C; Rossi S; Salvetti M; Tedeschi G; Tola MR; Trojano M; Zaffaroni M; Malucchi S; Bertolotto A; Capobianco M; et alii...